Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Prevail Therapeutics Inc. (PRVL)
|
|
| Cash Flow Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Sep-30-20 | Jun-30-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 | Jun-30-19 | Mar-31-19 | Dec-31-18 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Net income | -18.6 | -22.1 | -18.6 | -17.8 | -20.3 | -15.1 | -9.9 | -6.7 |
| Depreciation and amortization [+] | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| Depreciation | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| Stock-based compensation | 2.5 | 2.2 | 1.6 | 1.3 | 1.3 | 1.1 | 0.6 | 0.5 |
| Change in working capital [+] | -0.5 | 2.3 | 0.4 | 1.5 | 0.3 | 3.3 | -3.2 | 0.3 |
| Other current assets | -0.2 | 0.3 | 1.5 | 1.0 | -3.2 | 0.1 | -3.8 | 0.5 |
| Accounts payable | 0.6 | -2.0 | -1.2 | 0.2 | 2.9 | 0.1 | 0.7 | -0.9 |
| Other | -0.9 | 3.9 | 0.1 | 0.2 | 0.5 | 3.1 | -0.1 | 0.7 |
| Other operating activities | -0.2 | -0.9 | -1.8 | 0.2 | 0.1 | 0.5 | 0.1 | 0.3 |
| Cash from operations | -16.6 | -18.3 | -18.2 | -14.8 | -18.5 | -10.1 | -12.3 | -5.6 |
| |
| Capital expenditures | -0.2 | -0.1 | -0.3 | -0.1 | -0.5 | -1.3 | -0.3 | -0.3 |
| Purchases of property and equipment | -0.2 | -0.1 | -0.3 | -0.1 | -0.5 | -1.3 | -0.3 | -0.3 |
| Other cash from investing | -12.5 | -20.1 | | | | | | |
| Cash from investing | -12.7 | -20.2 | -0.3 | -0.1 | -0.5 | -1.3 | -0.3 | -0.3 |
| |
| Issuance of common stock, net | | | | | | 116.3 | | |
| Option exercises | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | | |
| Other cash from financing | 0.1 | 0.1 | 0.1 | -0.1 | 0.0 | -3.0 | 49.8 | |
| Cash from financing | 0.0 | 0.0 | 0.1 | -0.1 | 0.0 | 113.2 | 49.8 | 0.0 |
| |
| Free cash flow | -16.8 | -18.4 | -18.5 | -14.9 | -19.0 | -11.4 | -12.6 | -6.0 |
| Per share (diluted) | ($0.50) | ($0.55) | ($0.56) | ($0.52) | ($0.58) | ($0.44) | ($2.19) | ($1.16) |
|